WebmedCentral.com :: Article Review View

Lipoprotein Modification: A Hallmark in the Progression of Diabetic Nephropathy

Posted by Anonymous Reviewer on 23 Jun 2012 12:05:43 PM GMT

What are the main claims of the paper and how important are they?
The review article by Shiju & Pragasam highlights the role of LDL modification in the causation and/ progression of diabetic nephropathy.
Are these claims novel? If not, please specify papers that weaken the claims to the originality of this one.
NA
Are the claims properly placed in the context of the previous literature?

NA
Do the results support the claims? If not, what other evidence is required?

NA
If a protocol is provided, for example for a randomized controlled trial, are there any important deviations from it? If so, have the authors explained adequately why the deviations occurred?

NA
Is the methodology valid? Does the paper offer enough details of its methodology that its experiments or its analyses could be reproduced?

NA
Would any other experiments or additional information improve the paper? How much better would the paper be if this extra work was done, and how difficult would such work be to do, or to provide?

NA
Is this paper outstanding in its discipline? (For example, would you like to see this work presented in a seminar at your hospital or university? Do you feel these results need to be incorporated in your next general lecture on the subject?) If yes, what makes it outstanding? If not, why not?
NA
Other Comments:
This comprehensive review is interesting and informative with the authors clearly describing the various players involved in the pathophysiology of diabetic nephropathy (DN). the current strategies to avert or manage DN havent been all successful and thus it is warranted to re-look at the some of these mechansisms and evolve ways to avert onset or development of DN. The authors have also mentioned about thei ongoing work on the treatment strategies for prevention or delaying the onset and/or the progression of DNP. Therefore, It would be interesting to wait and see what their findings would turn out to be.
Competing interests:
None
Invited by the author to review this article? :
No
Have you previously published on this or a similar topic?:
No
References:
None
Experience and credentials in the specific area of science:

Biomedical scientist, Infectious diseases
How to cite: Anonymous.Lipoprotein Modification: A Hallmark in the Progression of Diabetic Nephropathy[Review of the article 'Lipoprotein Modification: A Hallmark in the Progression of Diabetic Nephropathy ' by Pragasam V].WebmedCentral 2012;3(6):WMCRW001965

Rating
Rating	1	2	3	4	5	6	7	8	9

Report abuse

Sweet and fatty: the role of oxidation and glycosylation of LDL in kidney injury in diabetes mellitus

Posted by Dr. Scott E Wenderfer on 25 May 2012 10:49:38 PM GMT

1	Is the subject of the article within the scope of the subject category?	Yes
2	Are the interpretations / conclusions sound and justified by the data?	Partly
3	Is this a new and original contribution?	Yes
4	Does this paper exemplify an awareness of other research on the topic?	Yes
5	Are structure and length satisfactory?	Yes
6	Can you suggest brief additions or amendments or an introductory statement that will increase the value of this paper for an international audience?	No
7	Can you suggest any reductions in the paper, or deletions of parts?	No
8	Is the quality of the diction satisfactory?	Yes
9	Are the illustrations and tables necessary and acceptable?	Yes
10	Are the references adequate and are they all necessary?	No
11	Are the keywords and abstract or summary informative?	Yes

Other Comments:
The manuscript is a good review of the potential injury causing mechanisms of oxidized LDL and glycated LDL in diabetic nephropathy, as identified by studies of kidney cells in vitro and animal models of diabetes. Clearly, the players are all introduced quite well: scavenger receptors, PPAR-gamma, VEGF, PDGF, TGF-beta, endothelians, CXCL12 (SR-PSOX), CCL2 (MCP1), renal mesangial cells, renal endothelial cells, podocytes, renal tubullar epithelial cells, and resident and infiltrating monocytes/macrophages. The question remains which pathways predominate and which pathways can be targetted specifically in the diabetic patient to protect from or reverse microalbuminuria. Several studies in the manuscript are covered that have shown benefits in these in vitro / animal modellng systems. However, responses in clinical practice with available pharmacologic agents and over the counter anti-oxidants have been disappointing. At points, the authors may overeach in their implications on the potential of currently available drugs. There are recent clinical trials of anti-oxidants that were not referenced, likely because they did not directly address the role of modified LDL. Clearly new agents need to be identified to manage this growing patient population. However, the authors correctly stress an important pathogenic mechanism - low density lipoporteins.

TGF-? needs to be changed to "TGF-beta" in the HTML and PDF versions of the paper
Competing interests:
None
Invited by the author to review this article? :
No
Have you previously published on this or a similar topic?:
No
References:
None
Experience and credentials in the specific area of science:

Board certified pediatric nephrologist, clinical glomerular disease experience, basic science immunologist and pathobiologist, mouse modeling experience
How to cite: Wenderfer S E.Sweet and fatty: the role of oxidation and glycosylation of LDL in kidney injury in diabetes mellitus [Review of the article 'Lipoprotein Modification: A Hallmark in the Progression of Diabetic Nephropathy ' by Pragasam V].WebmedCentral 2012;3(5):WMCRW001836

Rating
Rating	1	2	3	4	5	6	7	8	9

Report abuse

Reviews